CORPORATE BRIEFING SESSION 2025

GSK



Meeting link and Q&A via Vevox

MS Team Link for Attendees	https://teams.microsoft.com/meet/21808747253996?p=SPzzcXtOukvxrDV1 hs		
	Meeting ID: 218 087 472 539 96 Password: JX2Sa79n		
Posting of Q&As via Vevox	Login to https://vevox.app/#/m/136729806 Session ID: 136-729-806 Or scan the QR Code		



TABLE OF CONTENT

Company Overview



Economic Overview



Financial Outline



Q/A









Company Overview

Board of Directors



Ms. Lai Kuen Goh (Chairperson)



Ms. Erum Shakir Rahim (Chief Executive Officer)



Mr. Hasham Ali Baber (Chief Financial Officer)



Ms. Maheen Rahman (Independent Director)



Mr. Muneer Kamal (Independent Director)



Mr. Mehmood Mandviwalla (Non-Executive Director)



Ms. Ana Paula De Freitas Passos (Non-Executive Director)



Our purpose

We unite science, technology and talent to get ahead of disease together

How we'll get Ahead Together Our culture and thriving GSK people

Ambitious for patients

We're investing in innovation and growth at pace to achieve health impact at scale

Accountable for impact

We set focused objectives with clear measures of success

Do the right thing

We act responsibly and aim to lead the way on issues that matter





Our Key Brands





Calpol



Vates



Velosef





Top Employer Award

TOP EMPLOYER 2025

GSK Pakistan has been recognised as a Top Employer in Pakistan

Being certified as a Top Employer for five consecutive years reflects GSK Pakistan's dedication to a better world of work and exhibits this through excellent HR policies and people practices








Economic Overview

Economic Overview

CPI inflation %





Monetary Policy Rate %






- decline in interest rates by 11% over the past year
- FY 2025 GDP growth 2.7%





https://www.pbs.gov.pk/press-releases;

Economic Overview – Contd.

KSE - 100 (monthly average)













Financial Outline

Key Financial Highlights – YTD Sep 2025



Net Sales: 45 billion

(2024: 44 billion)



Gross Margin: 36%

(2024: 22%)



PBT: 10 billion

(2024: 6 billion)





EPS: 19.57

(2024: 11.25)




Key Financial Highlights – YTD Sep 2025 - Contd.





Return on Equity





Key Financial Ratios

Ratios	Sep 30, 2025	Sep 30, 2024
Return on equity	21%	14%
Current Ratio	1.88	1.68
Inventory days	164	125
Receivable days	4	4
Payable days	52	66





Questions & Answers